Drugs / elvorin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01333709 | May 2011 → Sep 2014 | rectal carcinoma | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 2 | NCT01248299 | Jan 2011 → Jan 2016 | esophageal squamous cell carcinoma | Centre Oscar Lambret | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04749108 Background | Nov 2021 → Aug 2026 overdue | rectal carcinoma | Institut du Cancer de Montpellier - Val d'Aurelle | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | elvorin | “A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous...” NCT01333709 ↗2“An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be...” NCT04749108 ↗ “Elvorin \[200 mg/m2, 2h IV, day 1 and day 2\]” NCT01248299 ↗ |
| Route | Intravenous | “Elvorin \[200 mg/m2, 2h IV, day 1 and day 2\]” NCT01248299 ↗ |